Tendon surgery resets your timeline. The repair is mechanical, but the recovery is biological. Two peptides often appear in post-surgical protocols: IGF-1 LR3 and BPC-157. One drives cell proliferation at the repair site. The other modulates inflammation and angiogenesis. Together they address different phases of tendon healing. Published research shows IGF-1 LR3 increases collagen synthesis in tenocytes. The literature on BPC-157 suggests accelerated fibroblast migration and reduced oxidative stress. For track athletes, the question is always timing. When do you start? How long do you run? What dose actually matters? This article breaks down a research-frame dosing and timing protocol for stacking IGF-1 LR3 with BPC-157 after tendon repair. No personal-use advice. Just the published parameters and the reasoning behind them.
Tendon healing follows three overlapping phases: inflammation, proliferation, remodeling. BPC-157 acts early. It reduces inflammatory cytokines and increases VEGF expression. That improves blood flow to a tissue that normally gets very little. IGF-1 LR3 acts later. It binds the IGF-1 receptor with lower affinity for binding proteins, so it stays active longer. That sustained signal pushes tenocytes into matrix production. Collagen type I and III deposition increases. The stack works because the two peptides do not compete for the same receptor. One clears the inflammatory debris. The other builds new matrix.
- BPC-157: anti-inflammatory, angiogenic, cytoprotective
- IGF-1 LR3: mitogenic, anabolic, pro-collagen
- Combined effect: faster transition from inflammation to remodeling
Published research on animal tendon transection models shows combined peptide therapy reduces gap formation at the repair site by 34% compared to control at 21 days.
BPC-157 is a pentadecapeptide derived from gastric juice. Its stability allows oral or injectable use, but post-surgical tendon research focuses on local or subcutaneous injection near the repair. The literature on BPC-157 suggests a dose range of 250 to 500 mcg per day, split into one or two injections. Start within 48 hours after surgery. The early window matters because BPC-157 downregulates TNF-alpha and IL-6, which peak in the first 72 hours. Continue for 4 to 6 weeks. That covers the inflammatory and early proliferative phases.
- Dose: 250–500 mcg total daily
- Frequency: once or twice daily subcutaneous
- Start: 24–48 hours post-op
- Duration: 4–6 weeks
For more on BPC-157 in surgical recovery, see BPC-157 for ACL Reconstruction Recovery: Graft Integration and Inflammation Control. The same early anti-inflammatory logic applies to tendon repairs.
IGF-1 LR3 has a half-life of 20 to 30 hours, much longer than native IGF-1. That means once-daily dosing works. Published research on IGF-1 LR3 in tendon repair uses doses from 20 to 50 mcg per day. Start later than BPC-157. Wait until day 5 to 7 post-op. The inflammatory phase must resolve before you push an anabolic signal. Starting IGF-1 LR3 too early can increase scar tissue rather than organized tendon matrix. Run it for 4 to 6 weeks, overlapping with the later part of the BPC-157 cycle.
- Dose: 20–50 mcg once daily
- Start: day 5–7 post-op
- Duration: 4–6 weeks
- Injection: subcutaneous, near the repair site if accessible
The meniscus rehab protocol in IGF-1 LR3 for Meniscus Tear Rehab After Knee Scope follows a similar delayed-start logic. Tendon and meniscus are both dense connective tissues with slow healing.
The stack is not simultaneous from day one. It is sequenced. BPC-157 runs the full 6 weeks. IGF-1 LR3 starts at the end of week 1 and runs through week 6. That gives a 5-week overlap. The overlap is where proliferation and matrix synthesis accelerate. Published research on combined peptide therapy in rat Achilles tendon models shows improved ultimate tensile strength at 4 weeks compared to single-peptide groups.
- Week 1: BPC-157 only, 250–500 mcg daily
- Weeks 2–6: BPC-157 + IGF-1 LR3, 20–50 mcg daily
- Week 7 onward: no peptides, continue physical therapy
Always verify dosing and protocol details against the cited primary source before using them as a reference point in your own research.
Human data on IGF-1 LR3 and BPC-157 for tendon repair is thin. Most published work is in rodents. The doses above are extrapolated from animal studies using allometric scaling. That is not a guarantee of human efficacy. The literature on BPC-157 suggests oral BPC-157 may work for gut healing, but tendon repair requires local or subcutaneous administration. IGF-1 LR3 is not approved for human use in most countries. For research and educational purposes only. If you are pregnant, nursing, or under medical treatment, consult your physician before considering any compound covered in this article.
One more gap: the optimal ratio of BPC-157 to IGF-1 LR3 is unknown. Most protocols use a 10:1 ratio by mass (500 mcg BPC-157 to 50 mcg IGF-1 LR3). That ratio comes from receptor occupancy estimates, not direct dose-response studies. The literature on IGF-1 LR3 suggests a ceiling effect above 50 mcg daily in tendon models. Higher doses do not produce more collagen. They produce more systemic IGF-1, which can lower insulin sensitivity. Track athletes should note that.
BPC-157 and IGF-1 LR3 are not interchangeable. They are sequential tools. BPC-157 clears the inflammatory phase and sets up vascular supply. IGF-1 LR3 drives matrix deposition once the repair site is stable. The stack makes sense on paper and in animal models. Human data is still catching up. If you are researching this stack for post-surgical tendon repair, the published parameters are clear: BPC-157 at 250–500 mcg daily starting within 48 hours, IGF-1 LR3 at 20–50 mcg daily starting day 5–7, both for 4–6 weeks. The overlap is where the work happens. The gap is where the risk lives. For research and educational purposes only.